Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：1
|
作者：
Shadman, Mazyar [1 ,2 ]
Mawad, Raya [3 ]
Dean, Carol [1 ]
Shannon-Dorcy, Kathleen [1 ]
Sandhu, Vicky [1 ]
Hendrie, Paul C. [2 ]
Scott, Bart L. [1 ,2 ]
Walter, Roland B. [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Pagel, John [1 ,2 ]
Estey, Elihu H. [2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Swedish Med Ctr, Seattle, WA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3732.3732
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A PHASE 2 STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH-RISK MYELODYSPLASTIC SYNDROME
    Cortes, J. E.
    Smith, B. D.
    Wang, E. S.
    Merchant, A.
    Oehler, V. G.
    Arellano, M.
    DeAngelo, D. J.
    Pollyea, D. A.
    Ma, W. W.
    Zeremski, M.
    Shaik, M. N.
    O'Connell, A.
    Chan, G.
    Schroeder, M. A.
    HAEMATOLOGICA, 2017, 102 : 50 - 50
  • [22] Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia
    Wei, Andrew
    Tan, Peter
    LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 675 - 676
  • [23] Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin
    Bow, EJ
    Gallant, G
    Williams, GJ
    Woloschuk, D
    Shore, TB
    Rubinger, M
    Schacter, BA
    CANCER, 1998, 83 (07) : 1344 - 1354
  • [24] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
    Assi, Rita
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Jabbour, Elias
    Jain, Nitin
    Daver, Naval
    Estrov, Zeev
    Uehara, Taisuke
    Owa, Takashi
    Cortes, Jorge E.
    Borthakur, Gautam
    CANCER, 2018, 124 (13) : 2758 - 2765
  • [25] A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Jabbour, Elias
    Kantarjian, Hagop
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Verstovsek, Srdan
    O'Brien, Susan
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    CANCER, 2011, 117 (06) : 1236 - 1244
  • [26] Induction of acute myeloid leukemia (AML) with idarubicin, cytarabine and cladribine (ICC).
    Wiedower, Eric
    Jamy, Omer Hassan
    Martin, Michael Gary
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Jabbour, Elias
    Borthakur, Gautam
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan
    Cortes, Jorge E.
    Yang, Hui
    Brandt, Mark
    Pierce, Sherry A.
    Newsome, Willie Mae
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 903 - 904
  • [28] High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia (AML).
    Larson, Sarah
    Campbell, Nicholas
    Huo, Dezheng
    Artz, Andrew
    Zhang, Yanming
    Gajria, Devika
    Green, Margaret
    Rahimova, Gamar
    Weiner, Howard
    Torres, Monica
    Odenike, Olatoyosi
    Godley, Lucy A.
    Rich, Elizabeth Shima
    Thirman, Michael
    Larson, Richard A.
    Stock, Wendy
    BLOOD, 2009, 114 (22) : 434 - 434
  • [29] Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Zavras, Phaedon D. D.
    Sinanidis, Ilias
    Tsakiroglou, Panagiotis
    Karantanos, Theodoros
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [30] Low-dose Cytarabine plus Aclarubicin for Patients with Previously Untreated Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Ineligible for Standard-dose Cytarabine plus Anthracycline
    Fukushima, Toshihiro
    Kawabata, Hiroshi
    Sawaki, Toshioki
    Satoh, Tomomi
    Nakamura, Takuji
    Iwao, Haruka
    Nakajima, Akio
    Sakai, Tomoyuki
    Miki, Miyuki
    Fujita, Yoshimasa
    Tanaka, Masao
    Kawanami, Takafumi
    Masaki, Yasufumi
    Okazaki, Toshiro
    Umehara, Hisanori
    ANTICANCER RESEARCH, 2012, 32 (04) : 1347 - 1353
12345